Privosegtor is advancing in the registrational PIONEER program across 2 key optic neuropathies, representing an unaddressed potential market of $7 billion in the U.S. Privosegtor achieved an average ...
Breakthrough Therapy Designation granted to Privosegtor, a neuroprotective candidate, for the treatment of optic neuritis Privosegtor is advancing ...
Breakthrough therapy designation granted as Company advances the PIONEER registrational program in optic neuropathies to create a potential ...
Oculis Holding AG (OCS) 44th Annual J.P. Morgan Healthcare Conference January 14, 2026 4:30 PM ESTCompany ParticipantsRiad Sherif - CEO ...
Morning Overview on MSN
Researchers think they’ve found a path to restoring human vision
For decades, restoring sight after severe eye damage sat firmly in the realm of science fiction. Now a wave of converging ...
The FDA has granted breakthrough therapy designation to privosegtor for optic neuritis, a common symptom of multiple ...
The US Food and Drug Administration has granted breakthrough therapy designation to Oculis’ neuroprotective candidate ...
The FDA granted breakthrough therapy designation to privosegtor, a novel peptoid small molecule for the treatment of optic ...
Oculis Holding (OCS) added ~11% on Tuesday after the Swiss drug developer announced the breakthrough therapy designation for ...
A diagnosis of uveal melanoma marks the beginning of a long-term relationship with your medical team. While the focus starts ...
Cold weather can significantly worsen multiple sclerosis symptoms, triggering stiffness, fatigue, and reduced mobility. Experts warn that low temperatures and limited sunlight may slow nerve ...
Collaborating institutions in Taiwan report higher risks of atopic disease among children conceived via assisted reproductive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback